- Home
- ATOS vs VTGN Comparison
ATOS vs VTGN Comparison
Compare ATOS & VTGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATOS
- VTGN
- Stock Information
- Founded
- ATOS 2009
- VTGN 1998
- Country
- ATOS United States
- VTGN United States
- Employees
- ATOS N/A
- VTGN N/A
- Industry
- ATOS Biotechnology: Pharmaceutical Preparations
- VTGN Biotechnology: Pharmaceutical Preparations
- Sector
- ATOS Health Care
- VTGN Health Care
- Exchange
- ATOS Nasdaq
- VTGN Nasdaq
- Market Cap
- ATOS 96.8M
- VTGN 82.7M
- IPO Year
- ATOS 2012
- VTGN N/A
- Fundamental
- Price
- ATOS $0.74
- VTGN $2.18
- Analyst Decision
- ATOS Strong Buy
- VTGN
- Analyst Count
- ATOS 3
- VTGN 0
- Target Price
- ATOS $7.13
- VTGN N/A
- AVG Volume (30 Days)
- ATOS 714.9K
- VTGN 126.6K
- Earning Date
- ATOS 05-12-2025
- VTGN 06-10-2025
- Dividend Yield
- ATOS N/A
- VTGN N/A
- EPS Growth
- ATOS N/A
- VTGN N/A
- EPS
- ATOS N/A
- VTGN N/A
- Revenue
- ATOS N/A
- VTGN $698,000.00
- Revenue This Year
- ATOS N/A
- VTGN N/A
- Revenue Next Year
- ATOS N/A
- VTGN N/A
- P/E Ratio
- ATOS N/A
- VTGN N/A
- Revenue Growth
- ATOS N/A
- VTGN N/A
- 52 Week Low
- ATOS $0.55
- VTGN $1.90
- 52 Week High
- ATOS $1.81
- VTGN $5.00
- Technical
- Relative Strength Index (RSI)
- ATOS 58.85
- VTGN 42.85
- Support Level
- ATOS $0.59
- VTGN $2.00
- Resistance Level
- ATOS $0.67
- VTGN $2.14
- Average True Range (ATR)
- ATOS 0.06
- VTGN 0.17
- MACD
- ATOS 0.01
- VTGN 0.01
- Stochastic Oscillator
- ATOS 88.47
- VTGN 58.33
About ATOS Atossa Therapeutics Inc.
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary innovative medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.
About VTGN VistaGen Therapeutics Inc.
Vistagen Therapeutics Inc is a biotechnology firm. The company is neuroscience-focused biopharmaceutical company dedicated to pursuing a pioneering approach to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on deep understanding of nose-to-brain neurocircuitry.